Valproic acid sensitizes chronic lymphocytic leukemia cells to apoptosis and restores the balance between pro- and antiapoptotic proteins

Molecular Medicine

Volumn 14, Issue 1-2, 2008, Pages 20-27

  Bokelmann, Imke ^b   Mahlknecht, Ulrich ^a,b  

^a SAARLAND UNIVERSITY   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 8; CASPASE 9; HISTONE; HISTONE DEACETYLASE INHIBITOR; PROTEIN BAX; PROTEIN BCL 2; VALPROIC ACID; APOPTOSIS REGULATORY PROTEIN; CASPASE 3; ENZYME INHIBITOR; HISTONE DEACETYLASE; PROTEIN BAK; PROTEIN BID;

ACETYLATION; ADULT; AGED; APOPTOSIS; ARTICLE; CELL DEATH; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; FLOW CYTOMETRY; HUMAN; MALE; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; SENSITIZATION; WESTERN BLOTTING; B CELL LEUKEMIA; B LYMPHOCYTE; CELL CULTURE; DRUG ANTAGONISM; DRUG EFFECT; METABOLISM; MIDDLE AGED; MITOCHONDRION; PATHOLOGY; REFERENCE VALUE;

ADULT; AGED; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; B-LYMPHOCYTES; BCL-2 HOMOLOGOUS ANTAGONIST-KILLER PROTEIN; BCL-2-ASSOCIATED X PROTEIN; BH3 INTERACTING DOMAIN DEATH AGONIST PROTEIN; CASPASE 3; CASPASE 8; CASPASE 9; ENZYME INHIBITORS; FEMALE; HISTONE DEACETYLASES; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MIDDLE AGED; MITOCHONDRIA; PROTO-ONCOGENE PROTEINS C-BCL-2; REFERENCE VALUES; TUMOR CELLS, CULTURED; VALPROIC ACID;

EID: 40349100607     PISSN: 10761551     EISSN: None     Source Type: Journal    
DOI: 10.2119/2007-00084.Bokelmann     Document Type: Article

References (27)

1. Chanan-Khan A, Porter CW. (2006) Immunomodulating drugs for chronic lymphocytic leukemia. Lancet Oncol. 7:480-8.
2. Bratton SB, MacFarlane M, Cain K, Cohen GM. (2000) Protein complexes activate distinct caspase cascades in death receptor and stress-induced apoptosis. Exp. Cell Res. 256:27-33.
3. Reed JC. (2000) Mechanisms of apoptosis. Am. J. Pathol. 157:1415-30.
4. Bodmer JL, Holler N, Reynard S, et al. (2000) TRAIL receptor-2 signals apoptosis through FADD and caspase-8. Nat. Cell Biol. 2:241-3.
5. Kischkel FC, Lawrence DA, Chuntharapai A, Schow P, Kim KJ, Ashkenazi A. (2000) Apo2L/TRAIL-dependent recruitment of endogenous FADD and caspase-8 to death receptors 4 and 5. Immunity 12:611-20.
6. Chang HY, Yang X. (2000) Proteases for cell suicide: functions and regulation of caspases. Microbiol. Mol. Biol. Rev. 64:821-46.
7. Schmitz I, Walczak H, Krammer PH, Peter ME. (1999) Differences between CD95 type I and II cells detected with the CD95 ligand. Cell Death Differ. 6:821-2.
8. Barnhart BC, Alappat EC, Peter ME. (2003) The CD95 type I/type II model. Semin. Immunol. 15:185-93.
9. Jewell AP. (2002) Role of apoptosis in the pathogenesis of B-cell chronic lymphocytic leukemia. Br. J. Biomed. Sci. 59:235-8.
10. Pepper C, Hoy T, Bentley DP. (1997) Bcl-2/Bax ratios in chronic lymphocytic leukemia and their correlation with in vitro apoptosis and clinical resistance. Br. J. Cancer 76:935-8.
11. Phiel CJ, Zhang F, Huang EY, Guenther MG, Lazar MA, Klein PS. (2001) Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen. J. Biol. Chem. 276:36734-41.
12. Mahlknecht U, Hoelzer D. (2000) Histone acetylation modifiers in the pathogenesis of malignant disease. Mol Med 6:623-644.
13. Johnstone RW, Licht JD. (2003) Histone deacetylase inhibitors in cancer therapy: is transcription the primary target? Cancer Cell 4:13-8.
14. Nebbioso A, Clarke N, Voltz E, et al. (2005) Tumor-selective action of HDAC inhibitors involves TRAIL induction in acute myeloid leukemia cells. Nat. Med. 11:77-84.
15. Insinga A, Monestiroli S, Ronzoni S, et al. (2005) Inhibitors of histone deacetylases induce tumor-selective apoptosis through activation of the death receptor pathway. Nat. Med. 11:71-6.
16. Marks P, Rifkind RA, Richon VM, Breslow R, Miller T, Kelly WK. (2001) Histone deacetylases and cancer: causes and therapies. Nat. Rev. Cancer 1:194-202.
17. Inoue S, MacFarlane M, Harper N, Wheat LM, Dyer MJ, Cohen GM. (2004) Histone deacetylase inhibitors potentiate TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in lymphoid malignancies. Cell Death Differ. 11(Suppl 2):S193-206.
18. MacFarlane M, Kohlhaas SL, Sutcliffe MJ, Dyer MJ, Cohen GM. (2005) TRAIL receptor-selective mutants signal to apoptosis via TRAIL-R1 in primary lymphoid malignancies. Cancer Res. 65:11265-70.
19. Muzio M, Salvesen GS, Dixit VM. (1997) FLICE induced apoptosis in a cell-free system: cleavage of caspase zymogens. J. Biol. Chem. 272:2952-6.
20. Stennicke HR, Jurgensmeier JM, Shin H, et al. (1998) Pro-caspase-3 is a major physiologic target of caspase-8. J. Biol. Chem. 273:27084-90.
21. Slee EA, Harte MT, Kluck RM, et al. (1999) Ordering the cytochrome c-initiated caspase cascade: hierarchical activation of caspases-2, -3, -6,-7, -8, and -10 in a caspase-9-dependent manner. J. Cell. Biol. 144:281-92.
22. Aron JL, Parthun MR, Marcucci G, et al. (2003) Depsipeptide (FR901228) induces histone acetylation and inhibition of histone deacetylase in chronic lymphocytic leukemia cells concurrent with activation of caspase 8-mediated apoptosis and downregulation of c-FLIP protein. Blood 102:652-8.
23. Lucas DM, Davis ME, Parthun MR, et al. (2004) The histone deacetylase inhibitor MS-275 induces caspase-dependent apoptosis in B-cell chronic lymphocytic leukemia cells. Leukemia 18:1207-14.
24. Sartorius UA, Krammer PH. (2002) Upregulation of Bcl-2 is involved in the mediation of chemotherapy resistance in human small cell lung cancer cell lines. Int. J. Cancer 97:584-92.
25. Robertson LE, Plunkett W, McConnell K, Keating MJ, McDonnell TJ. (1996) Bcl-2 expression in chronic lymphocytic leukemia and its correlation with the induction of apoptosis and clinical outcome. Leukemia 10:456-9.
26. Schmitz I, Kirchhoff S, Krammer PH. (2000) Regulation of death receptor-mediated apoptosis pathways. Int. J. Biochem. Cell Biol. 32:1123-36.
27. Igney FH, Krammer PH. (2002) Death and antideath: tumor resistance to apoptosis. Nat. Rev. Cancer 2:277-88.